secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVELATION BIOSCIENCES, INC. (REVB)
CIK:        0001810560
Form:       8-K
Filed at:   2022-01-14T23:59:59+00:00
Accession:  0001213900-22-002152
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.01, 9.01, 3.02, 5.01, 5.02, 5.03, 5.06
LLM model:  deepseek-v4-flash:cloud@v2

Revelation Biosciences (f/k/a Petra Acquisition) closes de-SPAC merger; new board appointed
--------------------------------------------------------------------------------

- Business combination of Petra Acquisition and Revelation Biosciences closed Jan 10, 2022; company renamed Revelation Biosciences.
- Holders of 3,480,362 Petra shares redeemed for ~$35.5M ($10.20/share); ~$7.6M escrowed, ~$4.2M released to company.
- Immediately post-closing: 12,944,213 common shares outstanding; 10,490,461 warrants and 460,706 RSUs outstanding.
- New board appointed: George Tidmarsh, James Rolke, Jennifer Carver, Jess Roper, Curt LaBelle; prior Petra directors/officers resigned.
- Petra ceased to be a shell company; common stock begins trading on Nasdaq under REVB, REVBU, REVBW.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810560/000121390022002152/0001213900-22-002152-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810560/000121390022002152/ea154019-8k_revelation.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-002152

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer